Abstract：
BACKGROUND: Neurofilament Light Chain (NfL) is a biomarker of axonal injury elevated in mild cognitive impairment (MCI) and Alzheimer\'s disease dementia. Blood NfL also inversely correlates with cognitive performance in those conditions. However, few studies have assessed NfL as a biomarker of global cognition in individuals demonstrating mild cognitive deficits who are at risk for vascular-related cognitive decline.
OBJECTIVE: To assess the relationship between blood NfL and global cognition in individuals with possible vascular MCI (vMCI) throughout cardiac rehabilitation (CR). Additionally, NfL levels were compared to age/sex-matched cognitively unimpaired (CU) controls.
METHODS: Participants with coronary artery disease (vMCI or CU) were recruited at entry to a 24-week CR program. Global cognition was measured using the Montreal Cognitive Assessment (MoCA) and plasma NfL level (pg/ml) was quantified using a highly sensitive enzyme-linked immunosorbent assay.
RESULTS: Higher plasma NfL was correlated with worse MoCA scores at baseline (β = -.352, P = .029) in 43 individuals with vMCI after adjusting for age, sex, and education. An increase in NfL was associated with worse global cognition (b[SE] = -4.81[2.06], P = .023) over time, however baseline NfL did not predict a decline in global cognition. NfL levels did not differ between the vMCI (n = 39) and CU (n = 39) groups (F(1, 76) = 1.37, P = .245).
CONCLUSIONS: Plasma NfL correlates with global cognition at baseline in individuals with vMCI, and is associated with decline in global cognition during CR. Our findings increase understanding of NfL and neurobiological mechanisms associated with cognitive decline in vMCI.
OBJECTIVE: To assess the relationship between blood NfL and global cognition in individuals with possible vascular MCI (vMCI) throughout cardiac rehabilitation (CR). Additionally, NfL levels were compared to age/sex-matched cognitively unimpaired (CU) controls.
METHODS: Participants with coronary artery disease (vMCI or CU) were recruited at entry to a 24-week CR program. Global cognition was measured using the Montreal Cognitive Assessment (MoCA) and plasma NfL level (pg/ml) was quantified using a highly sensitive enzyme-linked immunosorbent assay.
RESULTS: Higher plasma NfL was correlated with worse MoCA scores at baseline (β = -.352, P = .029) in 43 individuals with vMCI after adjusting for age, sex, and education. An increase in NfL was associated with worse global cognition (b[SE] = -4.81[2.06], P = .023) over time, however baseline NfL did not predict a decline in global cognition. NfL levels did not differ between the vMCI (n = 39) and CU (n = 39) groups (F(1, 76) = 1.37, P = .245).
CONCLUSIONS: Plasma NfL correlates with global cognition at baseline in individuals with vMCI, and is associated with decline in global cognition during CR. Our findings increase understanding of NfL and neurobiological mechanisms associated with cognitive decline in vMCI.
摘要：
背景：神经丝轻链（NfL）是轻度认知障碍（MCI）和阿尔茨海默病痴呆中轴索损伤升高的生物标志物。在这些情况下,血液NfL也与认知表现负相关。然而,在存在血管相关认知功能减退风险的轻度认知缺陷的个体中,很少有研究将NfL评估为总体认知功能的生物标志物.
目的：在整个心脏康复（CR）过程中，评估可能患有血管MCI（vMCI）的个体的血液NfL与整体认知之间的关系。此外,将NfL水平与年龄/性别匹配的认知未受损（CU）对照进行比较。
方法：冠状动脉疾病（vMCI或CU）的参与者在参加24周CR计划时被招募。使用蒙特利尔认知评估（MoCA）测量全球认知，并使用高度敏感的酶联免疫吸附测定法定量血浆NfL水平（pg/ml）。
结果：在校正年龄后，43例vMCI患者中，较高的血浆NfL与基线时较差的MoCA评分相关（β=-.352，P=.029），性别,和教育。NfL的增加与较差的整体认知相关(b[SE]=-4.81[2.06]，P=.023)随着时间的推移，然而,基线NfL并不能预测全球认知功能的下降.vMCI（n=39）和CU（n=39）组之间的NfL水平没有差异（F（1，76）=1.37，P=.245）。
结论：血浆NfL与vMCI患者基线时的整体认知相关，并与CR期间整体认知下降相关。我们的发现增加了对NfL和与vMCI认知下降相关的神经生物学机制的理解。
目的：在整个心脏康复（CR）过程中，评估可能患有血管MCI（vMCI）的个体的血液NfL与整体认知之间的关系。此外,将NfL水平与年龄/性别匹配的认知未受损（CU）对照进行比较。
方法：冠状动脉疾病（vMCI或CU）的参与者在参加24周CR计划时被招募。使用蒙特利尔认知评估（MoCA）测量全球认知，并使用高度敏感的酶联免疫吸附测定法定量血浆NfL水平（pg/ml）。
结果：在校正年龄后，43例vMCI患者中，较高的血浆NfL与基线时较差的MoCA评分相关（β=-.352，P=.029），性别,和教育。NfL的增加与较差的整体认知相关(b[SE]=-4.81[2.06]，P=.023)随着时间的推移，然而,基线NfL并不能预测全球认知功能的下降.vMCI（n=39）和CU（n=39）组之间的NfL水平没有差异（F（1，76）=1.37，P=.245）。
结论：血浆NfL与vMCI患者基线时的整体认知相关，并与CR期间整体认知下降相关。我们的发现增加了对NfL和与vMCI认知下降相关的神经生物学机制的理解。
